Opioid use and adverse health effects in breast cancer survivors
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae270 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Reina Haque und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, United States. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Analgesics, Opioid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: California Breast Cancer Research Program.
Abstract (Originalsprache)
Background
Little information exists on adverse effects related to opioid use in breast cancer survivors following active cancer treatment, and no studies included an age-matched comparison group. Thus, we examined opioid use and risk of falls, fractures, lung problems, and cardiovascular events in breast cancer survivors in the years following active cancer treatment along with a comparison group.
Methods
We conducted a longitudinal cohort study 33 989 breast cancer survivors and 157 609 age-matched women without cancer. Rates of adverse events, and multivariable hazards ratios for association between opioid use and the adverse health effects were calculated.
Results
Women with breast cancer had greater opioid use (60% vs 48%); longer median opioid duration (18 vs 16 days); and were prescribed stronger opioids than the matched cohort over 5.6 median years of follow-up. In multivariable models, the risk of falls was 12% higher (HR, 95% CI, 1.12 [1.07-1.17]), and fracture risk was 56% (HR = 1.56 [1.48-1.65]) greater in women with breast cancer who used opioids vs the matched cohort unexposed to opioids. In an analysis restricted to women with breast cancer, opioid use was strongly associated with the risk of falls (HR = 1.74 [1.63-1.85]); fractures (HR = 2.10 [1.95-2.27]); lung problems (HR = 1.53 [1.43-1.64]); and cardiovascular events (HR = 1.70 [1.39-2.08]) than opioid non-use.
Conclusions
After active cancer treatment, opioid use and high dosage use were common in breast cancer survivors, and were associated with increased risk for falls, lung problems, fractures, and cardiovascular events. Findings underscore the need for careful monitoring of opioid use in these survivors and the exploration of alternative pain management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, United States.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA 91101, United States.
- Alive & Well Women, South Pasadena, CA 91030, United States.
- The Lundquist Research Institute for Biomedical Innovation at UCLA-Harbor & Division of Medical Oncology and Hematology, Torrance, CA 90502, United States.
ORCID-Profile: Reina Haque
Förderung
- California Breast Cancer Research Program
Zitieren
APA
Haque, R., Chen, L. H., Shi, J., Gu, Z., Brady-Rogers, M., Chlebowski, R. T., & Hechter, R. C. (2025). Opioid use and adverse health effects in breast cancer survivors. The Oncologist. https://doi.org/10.1093/oncolo/oyae270
Vancouver
Haque R, Chen LH, Shi J, Gu Z, Brady-Rogers M, Chlebowski RT, et al. Opioid use and adverse health effects in breast cancer survivors. The Oncologist. 2025. doi:10.1093/oncolo/oyae270
BibTeX
@article{Haque2025,
author = {Haque, Reina and Chen, Lie Hong and Shi, Jiaxiao and Gu, Zheng and Brady-Rogers, Moira and Chlebowski, Rowan T and Hechter, Rulin C},
title = {Opioid use and adverse health effects in breast cancer survivors},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae270}
}
EUVIMED